Parents Receptive to Children Receiving HPV Vaccine at Certain Age

A recent study by Tietbohl et al., published in Pediatrics on June 2, 2025, presents compelling evidence for the feasibility and parental receptivity of initiating human papillomavirus (HPV) vaccination at an earlier age, specifically 9 to 10 years. This research holds significant implications for healthcare professionals, offering a pragmatic approach to optimizing HPV vaccine uptake and ultimately reducing the burden of HPV-associated cancers. For Black patients, this earlier intervention strategy is particularly critical, given persistent disparities in HPV vaccination rates and cervical cancer outcomes.

The study, an explanatory sequential mixed-methods analysis embedded within an ongoing randomized trial, examined clinician perceptions and parental receptivity across 17 practices in Colorado and 16 in California. The intervention arm initiated vaccination at ages 9 to 10 years, while the control group maintained the standard 11 to 12-year initiation. A substantial majority of clinicians surveyed (90% in Colorado and 77% in California) reported routinely initiating HPV vaccines at the earlier age. Crucially, clinicians largely perceived this earlier administration as “not burdensome,” with existing challenges such as parental concerns and discussion times remaining largely unchanged.

Semistructured interviews further illuminated parental perspectives. Many parents, interviewees noted, appeared receptive to discussing HPV vaccination at ages 9 to 10 years. Interestingly, pushback was more often linked to a child’s expectation of a vaccine-free visit at age 9, rather than inherent concerns about the HPV vaccine itself. A key finding was that discussions at this earlier age were often shorter, as sexual activity was not perceived as a salient topic. This suggests that framing the vaccine as a routine preventive health measure, rather than explicitly linking it to sexual health, may enhance acceptance among younger patients and their parents. Furthermore, the preference among many parents for spacing out vaccines, potentially administering a single vaccine at age 9 and fewer at age 11, presents a valuable strategy for integrating HPV vaccination into existing well-child visit schedules. The ongoing prospective trial will ultimately determine if this earlier initiation translates into improved vaccination completion rates, especially by age 13.

Why This Matters for Black Patients

The findings of this study are especially pertinent for addressing health disparities within the Black community. Despite recommendations, Black adolescents consistently exhibit lower HPV vaccination rates compared to their White counterparts. This disparity is multifaceted, stemming from a complex interplay of socioeconomic factors, access to care, healthcare provider communication, and vaccine hesitancy.

Cervical cancer, predominantly caused by HPV, disproportionately affects Black women. They experience higher incidence rates of cervical cancer and are twice as likely to die from the disease compared to White women. This grim statistic underscores the urgent need for effective preventive strategies, and HPV vaccination is a cornerstone of primary prevention.

Initiating HPV vaccination at ages 9 to 10 years offers several advantages that could specifically benefit Black patients:

• Increased Opportunity for Completion: Earlier initiation provides a longer window to complete the multi-dose series before adolescents become less engaged with routine healthcare visits. This is particularly important for families who may face barriers to consistent healthcare access, as it maximizes the likelihood of series completion.
• Reduced Stigma and Misconceptions: Discussing HPV vaccination at a younger age, before the onset of puberty or sexual activity, can de-link the vaccine from perceptions of sexual promiscuity. This reframing can be particularly impactful in communities where cultural or religious beliefs may contribute to vaccine hesitancy related to perceived sexual health implications. For Black families, where open discussions about sexual health may sometimes be challenging, an earlier, health-focused narrative around the vaccine can improve acceptance.
• Integration into Routine Care: By normalizing HPV vaccination at 9-10 years, it becomes another routine childhood immunization. This can help overcome “missed opportunities” for vaccination that often occur when providers wait until later adolescent visits, where other health priorities might overshadow vaccine discussions.
• Provider Comfort and Confidence: The study’s finding that clinicians perceive earlier administration as not burdensome is crucial. Empowering healthcare providers with the knowledge that these discussions are manageable and well-received by parents can increase their confidence in recommending the vaccine consistently across all patient populations, including Black patients who may benefit from proactive and culturally sensitive communication.
• Addressing Health Equity: Proactively targeting earlier vaccination among all children, including Black children, directly contributes to health equity by ensuring that all communities have an equal opportunity to benefit from this life-saving intervention. Closing the gap in HPV vaccination rates is a critical step towards eliminating the disproportionate burden of HPV-associated cancers in the Black community.

The Tietbohl et al. study provides a clear pathway for optimizing HPV vaccine delivery.